©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2016; 22(40): 8853-8861
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8853
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8853
Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma
Hee Chul Nam, Bohyun Jang, Myeong Jun Song, Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul 06591, South Korea
Myeong Jun Song, Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon 34943, South Korea
Author contributions: This manuscript was written completely by the stated authors.
Conflict-of-interest statement: There is no conflict of interest.
Correspondence to: Myeong Jun Song, MD, PhD, Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daeheung-ro 64, Jung-gu, Daejeon 34943, South Korea. mjsong95@gmail.com
Telephone: +82-42-2209291
Received: July 13, 2016
Peer-review started: July 18, 2016
First decision: August 8, 2016
Revised: August 25, 2016
Accepted: September 14, 2016
Article in press: September 14, 2016
Published online: October 28, 2016
Processing time: 105 Days and 3.5 Hours
Peer-review started: July 18, 2016
First decision: August 8, 2016
Revised: August 25, 2016
Accepted: September 14, 2016
Article in press: September 14, 2016
Published online: October 28, 2016
Processing time: 105 Days and 3.5 Hours
Core Tip
Core tip: Drug eluting beads are relatively new embolic agents that allow sustained release of chemotherapeutic agents in a localized fashion to the tumor. The advantage of DC bead transarterial chemoembolization (TACE) is a better combined ischemic and cytotoxic effect locally and less system toxicity when compared with conventional TACE.